Evidence map›Paper›PMID 27767381›Full record

ArticlePharmacogenomics2016

The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment.

Vinicius A Sortica, Juliana D Lindenau, Maristela G Cunha, Maria DO Ohnishi, Ana Maria R Ventura, Ândrea Kc Ribeiro-Dos-Santos, Sidney Eb Santos, Luciano Sp Guimarães, Mara H Hutz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacogenomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Influence ofAntimicrobial agents and chemotherapy · 2020
    Article
  12. Review
  13. Review
  14. Pharmacogenomics of COVID-19 therapies.NPJ genomic medicine · 2020
    Review
  15. Article
  16. Article
  17. A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications.European journal of drug metabolism and pharmacokinetics · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Vinicius A SorticaDepartamento de Genética, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Juliana D LindenauDepartamento de Genética, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Maristela G CunhaLaboratório de Microbiologia e Imunologia, Universidade Federal do Pará, Belém, PA, Brazil.
Maria DO OhnishiPrograma de Ensaios Clínicos em Malária, Instituto Evandro Chagas, Sistema de Vigilância Sanitária, Ministério da Saúde, Ananindeua, PA, Brazil.
Ana Maria R VenturaPrograma de Ensaios Clínicos em Malária, Instituto Evandro Chagas, Sistema de Vigilância Sanitária, Ministério da Saúde, Ananindeua, PA, Brazil.
Ândrea Kc Ribeiro-Dos-SantosLaboratório de Genética Humana e Médica, Universidade Federal do Pará, Belém, PA, Brazil.
Sidney Eb SantosLaboratório de Genética Humana e Médica, Universidade Federal do Pará, Belém, PA, Brazil.
Luciano Sp GuimarãesUnidade de Bioestatística, Grupo de Pesquisa e Pós Graduação, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Mara H HutzDepartamento de Genética, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Universidade Federal do Pará · BRUniversidade Federal do Rio Grande do Sul · BRHospital de Clínicas de Porto Alegre · BRInstituto Evandro Chagas · BRMinistério da Saúde · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChloroquine/primaquine is the current therapy to eliminate Plasmodium vivax infection in the Amazon region.

aimsThis study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic polymorphisms influence on cloroquine/primaquine treatment. PATIENTS &

methodsGeneralized estimating equations analyses were performed to determine the genetic influence in parasitemia and/or gametocytemia clearance over treatment time in 164 patients.

resultsAn effect of CYP2C8 low-activity alleles on treatment was observed (p = 0.01). From baseline to first day of treatment, wild-type individuals achieved greater reduction of gametocytes than low-activity allele carriers. CYP2C9 and CYP3A5 genes showed a trend for gametocytemia and parasitemia clearance rates.

conclusionFuture studies should be performed to access the extent of CYP2C8, CYP2C9 and CYP3A5 gene polymorphisms influence on cloroquine/primaquine treatment.

Indexed as

chloroquinemalariapharmacogenomicsprimaquinetreatment

Identifiers

PMID27767381
PMCPMC7099632
OpenAlexW2535054637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.